Erdafitinib versus enfortumab vedotin in previously treated urothelial carcinoma

Video

Michael Devitt, MD, a hematologist/oncologist and assistant professor at the University of Virginia Medical Center, discusses considerations when choosing between erdafitinib and enfortumab vedotin in previously treated urothelial carcinoma.

Erdafitinib (Balversa) is approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Enfortumab vedotin-ejfv (Padcev) is approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

Related Videos
James Ferguson III, MD, PhD, answers a question during a Zoom video interview
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Illustration of human urinary bladder | Image Credit:  © magicmine - stock.adobe.com
Sandip M. Prasad, MD, MPhil, answers a question during a Zoom video interview
3d rendered illustration - bladder cancer | © SciePro - stock.adobe.com
Sandip M. Prasad, MD, MPhil, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.